

Assay Guidance Workshop for High-Throughput Screening and Lead Discovery

Tuesday Sept 24, 2024 – Wednesday Sept 25, 2024
1 Lilly Corporate Ctr, Indianapolis, IN 46285

AGENDA: Day 1

- 10:00 AM **The NCATS Assay Guidance Manual Program: Advancing the Practice and Rigor of Preclinical Translation**
Sarine Markossian, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
- 10:15 AM **Session 1: Target ID/Validation and Assay Development**
- 10:15 AM **Target Identification and Validation**
TBD
- 11:00 AM **Strategies for Assay Selection and for the Development of Robust Biochemical Assays**
Nathan Coussens, Frederick National Laboratory for Cancer Research
- 11:45 AM **Treating Cells as Reagents and Measuring Viable, Dead, or Apoptotic Cell Number as Orthogonal Controls to Design Reproducible Assays**
Terry Riss, Promega Corporation
- 12:30 PM **Lunch Break**
- 1:30 PM **Session 2: HTS Assay Interpretation, Statistics and Data Analysis**
- 1:30 PM **Assay Interpretation: Studies in Mechanisms and Methods in Assay Interferences**
Douglas Auld, Novartis Institutes for BioMedical Research
- 2:15 PM **Basic Assay Statistics, Data Analysis & Rules of Thumb (ROT)**
Thomas Chung, Sanford Burnham Prebys Medical Discovery Institute
- 3:00 PM **Break**
- 3:30 PM **Session 2: (continued)**
- 3:30 PM **Reproducibility Assessment of *In Vitro* Screening Results**
Philip Iversen, Luther College
- 4:15 PM **AGM Data Analysis Webtools Hands-on Training**
Philip Iversen, Luther College
Jason Manro, Eli Lilly and Company
Jeffrey Weidner, QualSci Consulting
- 5:00 PM **Adjourn**
- 6:00 PM **Networking Social**

AGENDA: Day 2

8:30 AM – 9:30 AM	Tour of Eli Lilly Facilities
9:50 AM	Welcome and Today's Agenda Sarine Markossian, NCATS, NIH
10:00 AM	Session 3: Biophysical Approaches
10:00 AM	Small Molecule Discovery and Target Interaction Validation Using Biophysical Techniques Michael Ronzetti, NCATS
10:45 AM	Introduction to Mass Spectrometry for Drug Screening and Lead Optimization Mackenzie Pearson, Eli Lilly and Company
11:30 AM	Session 4: Lead Optimization
11:30 AM	<i>In Vitro</i> Assessments of ADME Properties of Lead Compounds Mike Mohutsky, Eli Lilly and Company
12:15 PM	Lunch Break
1:15 PM	Session 4: (continued)
1:15 PM	PK/PD Concepts for <i>in vitro</i>/ <i>in vivo</i> Assays TBD
2:00 PM	Session 5: New Modalities and Novel Trends
2:00 PM	ADC Assay Development and Design, Best Practices Carmen M Pérez, Eli Lilly and Company
2:45 PM	Break
3:15 PM	Session 5: (continued)
3:15 PM	Drug Screening with Engineered 3D Tissue Models Marc Ferrer, NCATS, NIH
4:00 PM	Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries Timothy Foley, Pfizer
4:45 PM	Open discussion and additional Q&A
5:00 PM	Adjourn